Development of a population pharmacokinetics and pharmacodynamics model of glucarpidase rescue treatment after high-dose methotrexate therapy

• Published in: Frontiers in oncology 2023-01, Vol.13, p.1003633-1003633
• Main Authors: Fukaya, Yutaka, Kimura, Toshimi, Hamada, Yukihiro, Yoshimura, Kenichi, Hiraga, Hiroaki, Yuza, Yuki, Ogawa, Atsushi, Hara, Junichi, Koh, Katsuyoshi, Kikuta, Atsushi, Koga, Yuhki, Kawamoto, Hiroshi
• Format: Article
• Language: English
• Subjects: glucarpidase; methotrexate - adverse effects; Oncology; pharmacodynamics; pharmacokinetics; safety
• ISSN: 2234-943X; 2234-943X
• DOI: 10.3389/fonc.2023.1003633

Glucarpidase (CPG2) reduces the lethal toxicity of methotrexate (MTX) by rapid degradation. In this study, a CPG2 population pharmacokinetics (popPK) analysis in healthy volunteers (phase 1 study) and a popPK-pharmacodynamics (popPK-PD) analysis in patients (phase 2 study, = 15) who received 50 U/kg of CPG2 rescue for delayed MTX excretion were conducted. In the phase 2 study, the first CPG2 treatment at a dose of 50 U/kg was intravenously administered for 5 min within 12 h after the first confirmation of delayed MTX excretion. The second dose of CPG2, with a plasma MTX concentration >1 μmol/L, was administered to the patient more than 46 h after the start of CPG2 administration. The population mean PK parameters (95% CI) of MTX, obtained from the final model , were estimated as follows: = 2.424 L/h (95% CI: 1.755-3.093), = 12.6 L (95% CI: 10.8-14.3), = 2.15 L (95% CI: 1.60-2.70), and = 8.131 x 10 (4.864 x 10 -11.398 x 10 ). The final model, including covariates, was (L/h): 3.248 x / 60 (CV 33.5%), (L): 0.386 x (CV 29.1%), (L):3.052 x /60 (CV 90.6%), and (L/h): 6.545 x 10 (CV 79.8%). These results suggest that the pre-CPG2 dose and 24 h after CPG2 dosing were the most important sampling points in the Bayesian estimation of plasma MTX concentration prediction at 48 h. These CPG2-MTX popPK analysis and Bayesian estimation of rebound in plasma MTX concentrations are clinically important to estimate >1.0 μmol/L 48 h after the first CPG2 dosing. https://dbcentre3.jmacct.med.or.jp/JMACTR/App/JMACTRS06/JMACTRS06.aspx?seqno=2363, identifier JMA-IIA00078 and https://dbcentre3.jmacct.med.or.jp/JMACTR/App/JMACTRS06/JMACTRS06.aspx?seqno=2782, identifier JMA-IIA00097.